本帖最后由 老马 于 2012-1-13 21:20 编辑
' C/ e5 H! d1 R! L( E. P1 l' `0 ~. P4 D$ f
爱必妥和阿瓦斯丁的比较0 [/ [8 J9 t! R
8 D# K5 k/ I6 rhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/2 B4 R0 d$ v0 K* F+ B1 m; f$ u
2 c" B8 v' z( p. m( E
2 p; j- b% e+ X; B) bhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
1 _& U6 f. c3 V$ g==================================================3 S: D& ]$ z; o" g* j9 [0 z [
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)# c% T0 R+ ]8 [" d# O4 \$ U
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.- G$ l, J0 f& `" ^; v2 w( a
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
- G7 F! E) N! f
|